Dutch diagnostics giant Qiagen grabbed Ingenuity Systems in a $105 million cash deal, giving it new technology to boost the analysis of genomic data for molecular diagnostics.
What's a birth-control drug maker to do when its pills start to flag? Turn to a device instead. That's the strategy Bayer is using to bolster its contraceptives business, with plans to spend $1.1 billion in cash to buy California-based Conceptus and its Essure birth-control product.
Valeant Pharmaceuticals was on the verge of its biggest deal yet last week. Until merger talks with generics giant Actavis fell apart, that is.
Bayer AG will snatch up California birth control device maker Conceptus for a $1.1 billion, a move that helps the German maker of drugs and chemicals add to its women's health products. Investors reacted strongly, driving the Conceptus's stock up more than 19% to nearly $31, in late morning trading on April 29.
Score one for the plaintiffs in Takeda Pharmaceuticals' Actos litigation. A California jury weighed in against the drugmaker, deciding that Takeda didn't do enough to warn patient Jack Cooper about a heightened risk of bladder cancer.
Thermo Fisher is in the process of closing its planned $13.6 billion takeover of Life Technologies, but a Life shareholder is suing to block the deal, saying the company is selling itself too cheap in an unfair bidding process.
Theravance announced Thursday afternoon that it plans to break apart into two publicly traded companies: a company dubbed Royalty Management that will take over Theravance's late-stage respiratory drugs and another called Theravance Biopharma focused on small-molecule R&D.
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
OPKO Health announced today that it is poised to acquire Israel-based Prolor Biotech in an all-stock transaction valued at $480 million, or $7 per share of Prolor common stock.
Here's a multibillion-dollar question: With their improved cash positions, will pharma companies increase spending this year on acquisitions? Over at Moody's, analysts predict that the answer to this question will be "yes" and deep-pocketed pharma companies will spend big dollars on M&A deals.